- Home
- TROO vs GOSS Comparison
TROO vs GOSS Comparison
Compare TROO & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TROO
- GOSS
- Stock Information
- Founded
- TROO 2005
- GOSS 2015
- Country
- TROO Hong Kong
- GOSS United States
- Employees
- TROO N/A
- GOSS N/A
- Industry
- TROO Radio And Television Broadcasting And Communications Equipment
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- TROO Technology
- GOSS Health Care
- Exchange
- TROO Nasdaq
- GOSS Nasdaq
- Market Cap
- TROO N/A
- GOSS 262.5M
- IPO Year
- TROO N/A
- GOSS 2019
- Fundamental
- Price
- TROO $0.68
- GOSS $1.25
- Analyst Decision
- TROO
- GOSS Strong Buy
- Analyst Count
- TROO 0
- GOSS 4
- Target Price
- TROO N/A
- GOSS $7.75
- AVG Volume (30 Days)
- TROO 52.4K
- GOSS 2.6M
- Earning Date
- TROO 07-07-2025
- GOSS 08-11-2025
- Dividend Yield
- TROO N/A
- GOSS N/A
- EPS Growth
- TROO N/A
- GOSS N/A
- EPS
- TROO N/A
- GOSS N/A
- Revenue
- TROO $10,073,000.00
- GOSS $124,590,000.00
- Revenue This Year
- TROO N/A
- GOSS N/A
- Revenue Next Year
- TROO N/A
- GOSS $91.14
- P/E Ratio
- TROO N/A
- GOSS N/A
- Revenue Growth
- TROO 182.24
- GOSS N/A
- 52 Week Low
- TROO $0.49
- GOSS $0.66
- 52 Week High
- TROO $4.89
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- TROO 43.70
- GOSS 50.10
- Support Level
- TROO $0.65
- GOSS $1.20
- Resistance Level
- TROO $0.71
- GOSS $1.44
- Average True Range (ATR)
- TROO 0.08
- GOSS 0.10
- MACD
- TROO -0.02
- GOSS -0.02
- Stochastic Oscillator
- TROO 8.39
- GOSS 22.45
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.